Physician profile
Robert C Ammlung
NPI 1649225731
$4,061.02
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,834 · 2020: $1,220 · 2021: $1,007.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $386.46 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $385.89 | 2019-2021 | |
| Glaxosmithkline, LLC. | $310.58 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $306.19 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $299.34 | 2019 | |
| Novo Nordisk INC | $275.16 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $272.45 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.08 | 2019-2021 | |
| Pfizer INC. | $219.54 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $189.62 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.71 | 2019-2021 | |
| Allergan, INC. | $178.36 | 2020 | |
| Amgen INC. | $129.92 | 2019-2021 | |
| Astellas Pharma US INC | $124.99 | 2019 | |
| Amarin Pharma, INC. | $101.61 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $87.65 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $80.91 | 2021 | |
| Horizon Therapeutics Plc | $63.68 | 2019-2020 | |
| Eisai INC. | $57.79 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $48.06 | 2019-2020 | |
| Medtronic USA, INC. | $40.29 | 2019-2020 | |
| Abbvie INC. | $26.81 | 2021 | |
| Medicure Pharma INC. | $20.56 | 2021 | |
| Zyla Life Sciences, INC. | $16.24 | 2019 | |
| Sanofi Pasteur INC. | $15.13 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ammlung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.